Vikram R Bollineni1, Michel J B Koole2, Jan Pruim2, Charlotte L Brouwer3, Erwin M Wiegman3, Harry J M Groen4, Renske Vlasman3, Gyorgy B Halmos5, Sjoukje F Oosting6, Johannes A Langendijk3, Joachim Widder3, Roel J H M Steenbakkers3. 1. University of Groningen, Department of Radiation Oncology, The Netherlands. Electronic address: bollinenivr@yahoo.com. 2. University of Groningen, Department of Nuclear Medicine and Molecular Imaging, The Netherlands. 3. University of Groningen, Department of Radiation Oncology, The Netherlands. 4. University of Groningen, Department of Pulmonary Diseases, The Netherlands. 5. University of Groningen, Department of Otolaryngology, Head and Neck Surgery, The Netherlands. 6. University of Groningen, Department of Medical Oncology, The Netherlands.
Abstract
INTRODUCTION: To define the optimal time point for the integration of hypoxia (18)F-FAZA-PET/CT information into radiotherapy treatment planning to benefit from hypoxia modification or dose escalation treatment. Therefore, we performed a prospective cohort study, using serial hypoxic imaging ((18)F-FAZA-PET/CT) prior to and at several time-points during (chemo)radiotherapy (CHRT) in six head and neck squamous cell (HNSCC) and six non-small cell lung cancer (NSCLC) patients. METHODS: The spatio-temporal dynamics of tumor hypoxia and fractional hypoxic volumes (FHV) were evaluated using a voxel-by-voxel analysis based on a (18)F-FAZA-T/B ratio of 1.4 at four time points in HNSCC patients, at baseline (FAZA-BL), at week one (FAZA-W1), two (FAZA-W2), and four (FAZA-W4) during CHRT and at three time points in NSCLC patients (baseline; W2, W4). RESULTS: Ten out of twelve patients showed a substantial pre-treatment tumor hypoxia representing a FHV⩾1.4 assessed by (18)F-FAZA-PET/CT. The median FHV was 38% (FAZA-BL), 15% (FAZA-W1), 17% (FAZA-W2) and 1.5% (FAZA-W4) in HNSCC patients, and 34% (FAZA-BL), 26% (FAZA-W2) and 26% (FAZA-W4) in NSCLC patients, respectively. Stable tumor hypoxia was observed in three HNSCC patients and two NSCLC patients at FAZA-W2. In three HNSCC patients and two NSCLC patients FHVs declined to non-detectable hypoxia levels at FAZA-W4 during CHRT, while two NSCLC patients, showed increasing FHVs. CONCLUSION: Our results indicate that, instead of using the FAZA-BL scan as the basis for the dose escalation, FAZA-W2 of CHRT is most suitable and might provide a more reliable basis for the integration of (18)F-FAZA-PET/CT information into radiotherapy treatment planning for hypoxia-directed dose escalation strategies.
INTRODUCTION: To define the optimal time point for the integration of hypoxia (18)F-FAZA-PET/CT information into radiotherapy treatment planning to benefit from hypoxia modification or dose escalation treatment. Therefore, we performed a prospective cohort study, using serial hypoxic imaging ((18)F-FAZA-PET/CT) prior to and at several time-points during (chemo)radiotherapy (CHRT) in six head and neck squamous cell (HNSCC) and six non-small cell lung cancer (NSCLC) patients. METHODS: The spatio-temporal dynamics of tumor hypoxia and fractional hypoxic volumes (FHV) were evaluated using a voxel-by-voxel analysis based on a (18)F-FAZA-T/B ratio of 1.4 at four time points in HNSCC patients, at baseline (FAZA-BL), at week one (FAZA-W1), two (FAZA-W2), and four (FAZA-W4) during CHRT and at three time points in NSCLCpatients (baseline; W2, W4). RESULTS: Ten out of twelve patients showed a substantial pre-treatment tumor hypoxia representing a FHV⩾1.4 assessed by (18)F-FAZA-PET/CT. The median FHV was 38% (FAZA-BL), 15% (FAZA-W1), 17% (FAZA-W2) and 1.5% (FAZA-W4) in HNSCC patients, and 34% (FAZA-BL), 26% (FAZA-W2) and 26% (FAZA-W4) in NSCLCpatients, respectively. Stable tumor hypoxia was observed in three HNSCC patients and two NSCLCpatients at FAZA-W2. In three HNSCC patients and two NSCLCpatients FHVs declined to non-detectable hypoxia levels at FAZA-W4 during CHRT, while two NSCLCpatients, showed increasing FHVs. CONCLUSION: Our results indicate that, instead of using the FAZA-BL scan as the basis for the dose escalation, FAZA-W2 of CHRT is most suitable and might provide a more reliable basis for the integration of (18)F-FAZA-PET/CT information into radiotherapy treatment planning for hypoxia-directed dose escalation strategies.
Authors: Vlad C Sandulache; Yunyun Chen; Heath D Skinner; Tongtong Lu; Lei Feng; Laurence E Court; Jeffrey N Myers; Raymond E Meyn; Clifton D Fuller; James A Bankson; Stephen Y Lai Journal: Mol Cancer Ther Date: 2015-09-16 Impact factor: 6.261
Authors: Jon Cacicedo; Arturo Navarro; Olga Del Hoyo; Alfonso Gomez-Iturriaga; Filippo Alongi; Jose A Medina; Olgun Elicin; Andrea Skanjeti; Francesco Giammarile; Pedro Bilbao; Francisco Casquero; Berardino de Bari; Alan Dal Pra Journal: Br J Radiol Date: 2016-08-02 Impact factor: 3.039
Authors: Constantin Lapa; Ursula Nestle; Nathalie L Albert; Christian Baues; Ambros Beer; Andreas Buck; Volker Budach; Rebecca Bütof; Stephanie E Combs; Thorsten Derlin; Matthias Eiber; Wolfgang P Fendler; Christian Furth; Cihan Gani; Eleni Gkika; Anca-L Grosu; Christoph Henkenberens; Harun Ilhan; Steffen Löck; Simone Marnitz-Schulze; Matthias Miederer; Michael Mix; Nils H Nicolay; Maximilian Niyazi; Christoph Pöttgen; Claus M Rödel; Imke Schatka; Sarah M Schwarzenboeck; Andrei S Todica; Wolfgang Weber; Simone Wegen; Thomas Wiegel; Constantinos Zamboglou; Daniel Zips; Klaus Zöphel; Sebastian Zschaeck; Daniela Thorwarth; Esther G C Troost Journal: Strahlenther Onkol Date: 2021-07-14 Impact factor: 3.621
Authors: Nuradh Joseph; Norman F Kirkby; Peter J Hoskin; Catharine M L West; Ananya Choudhury; Roger G Dale Journal: Br J Radiol Date: 2020-06-02 Impact factor: 3.039
Authors: Gerald S M A Kerner; Vikram R Bollineni; Thijo J N Hiltermann; Nanna M Sijtsema; Alexander Fischer; Alphons H H Bongaerts; Jan Pruim; Harry J M Groen Journal: EJNMMI Res Date: 2016-04-18 Impact factor: 3.138
Authors: Catharina M L Zegers; Frank J P Hoebers; Wouter van Elmpt; Judith A Bons; Michel C Öllers; Esther G C Troost; Daniëlle Eekers; Leo Balmaekers; Marlies Arts-Pechtold; Felix M Mottaghy; Philippe Lambin Journal: Eur J Nucl Med Mol Imaging Date: 2016-06-01 Impact factor: 9.236